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BACKGROUND: Diagnosis of Cushing syndrome requires
a multistep process that includes verification of hypercor-
tisolism followed by identification of the cause of adre-
nocortical hyperfunction. This study assessed whether
pituitary, ectopic, and adrenal subtypes of Cushing syn-
drome were characterized by distinct plasma steroid pro-
files that might assist diagnosis.
METHODS: In this retrospective cross-sectional study,
mass spectrometricmeasurements of a panel of 15 plasma
steroids were applied to 222 patients tested for Cushing
syndrome. Disease was excluded in 138 and confirmed
in 51 patients with pituitary Cushing syndrome, 12 with
ectopic adrenocorticotropin secretion, and 21 with adrenal
disease. Another 277 age- and sex-matched hypertensive
andnormotensive volunteerswere included for comparison.
RESULTS: Compared with patients without disease, the
largest increases in plasma steroids among patients with
Cushing syndrome were observed for 11-deoxycortisol
(289%), 21-deoxycortisol (150%), 11-deoxycorticosterone
(133%), corticosterone (124%), and cortisol (122%). Pa-
tients with ectopic disease showed the most prominent
increases, but there was considerable variation for other
steroids according to subtype. Patients with adrenal dis-
ease had the lowest concentrations of androgens, whereas
those with ectopic and pituitary disease showed the low-
est concentrations of aldosterone. Plasma 18-oxocortisol
was particularly low in ectopic disease.With the use of 10
selected steroids, subjects with and without different
Cushing syndrome subtypes could be discriminated
nearly as closely as with the use of salivary and urinary free
cortisol, dexamethasone-suppressed cortisol, and plasma
adrenocorticotropin (9.5% vs 5.8% misclassification).
CONCLUSIONS: Patients with different subtypes of Cush-
ing syndrome show distinctive plasma steroid profiles
that may offer a supplementary single-test alternative for
screening purposes.
© 2017 American Association for Clinical Chemistry
Hypercortisolism in endogenous Cushing syndrome
(CS) is a condition associated with poor quality of life
and high morbidity that if left untreated carries a median
survival of 5 years (1 ). Prompt diagnosis to ensure
appropriately tailored therapy is therefore crucial for im-
proved outcomes. This, however, is complicated by a
multistep diagnostic process necessary not only to iden-
tify patients with CS but also the particular subtype.
According to current guidelines (2 ), initial testing
for CS should follow appropriate clinical suspicion and
include at least 1 of the following tests: measurements of
urinary or salivary free cortisol; a 1 mg overnight or 2 mg
longer-duration dexamethasone suppression test (DST).
Positive results are followed up by repeat or other tests of
the screening combination to confirm disease. On con-
firmation, further testing is directed at distinguishing
adrenocorticotropin (ACTH)-independent CS, due to
autonomous cortisol secretion by an adrenal adenoma
or bilateral adrenal nodular disease, from ACTH-
dependent CS, usually reflecting an ACTH-secreting pi-
tuitary adenoma or more rarely due to ectopic ACTH
secretion. For ACTH-dependent CS, a variety of further
dynamic tests and imaging procedures are necessary to
distinguish pituitary from ectopic subtypes and locate the
source of ACTH or in occasional cases corticotropin-
releasing hormone.
Although several early studies documented the use
of plasma or urinary multisteroid profiles for character-
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izing patients with CS, the methods involved cumber-
some paper or liquid chromatography and immunoassay
procedures (3–5 ) or gas chromatography following der-
ivatization (6, 7 ) and have not enjoyed continuing use.
Nevertheless, several of these reports indicated distinct
steroid profiles that could be useful for differential diag-
nosis of CS (3–5 ). More recently LC-MS/MS has come
to the forefront for not only routine measurements of
serum, urinary free, or salivary cortisol (8–10) but also
multisteroid profiling in disorders of adrenocortical
function such as congenital adrenal hyperplasia (11, 12 ),
adrenal insufficiency (12, 13 ), and primary aldosteron-
ism (14, 15 ). There has also been 1 report on the appli-
cation of LC-MS/MS–based multisteroid profiling in
subclinical CS (16 ) and 2 other recent reports directed to
small series of patients with adrenocortical carcinoma
and CS (17, 18 ).
On the basis of the above considerations and follow-
ing promising findings of early studies examining urinary
and serum steroid metabolomes in CS (3–7 ), we hypoth-
esized that the 3 main subtypes of CS would show differ-
ences in plasma steroid profiles that might prove useful
for disease identification and stratification. To address
this hypothesis, we employed a newly developed LC-
MS/MS method to measure 15 adrenal steroids in single
plasma samples collected from 222 patients tested for CS,
among whom disease was confirmed in 84 patients. Dis-
ease was excluded in the other 138 patients by conven-
tional diagnostic testing. For comparative purposes a
further 277 age- and sex-matched normotensive and hy-
pertensive volunteers were selected from a previously de-
scribed reference population (19 ).
Materials and methods
SUBJECTS
We performed a bicentric cross-sectional study (as part of
the German Cushing Registry) analyzing 222 study par-
ticipants tested for CS at the Ludwig Maximilians Uni-
versität Mu¨nchen (n 161) and the University Hospital
Dresden (n 61). Details of the German Cushing Reg-
istry have been described elsewhere (20 ). CS was con-
firmed or excluded on the basis of results of conventional
diagnostic testing and follow-up (Table 1). Patients with
subclinical hypercortisolism, defined by the absence of
typical signs and symptoms of CS in the presence of
abnormal biochemical test results for hypercortisolism,
were excluded from the analysis. The 277 normotensive
and hypertensive volunteers included for comparative
purposes were selected on the basis of a match for age and
sex from a larger population of 525 volunteers (all from
Dresden) used for establishing age- and sex-specific ref-
erence intervals for each of the steroids of the plasma
panel (19 ). Subjects provided written informed consent
under protocols approved by the local ethics committee
at each center.
DIAGNOSIS OF CS
Diagnosis of CS followed current guidelines (2 ). In
short, initial screening was based on the presence of rel-
evant clinical features and biochemical confirmation
through the following screening tests: increased 24-h uri-
nary free cortisol according to the upper cutoffs of refer-
ence intervals; loss of diurnal circadian rhythm in salivary
cortisol with midnight salivary cortisol concentrations
Table 1. Demographic patient data and routine biochemical test results for patients screened for CS according to diagnosis.
Diagnosis Reference
Patients tested for CS
Excluded Adrenal Pituitary Ectopic
Demographics
N 277 138 21 51 12
Sex (M/F) 99/178 49/89 3/18 16/35 5/7
Age (years)a 47 (18–81) 46 (16–80) 47 (17–72) 48 (17–78) 53 (26–75)
Routine Biochemistry
Urine free cortisol (μg/24 h)a 143 (4–530) 603b (83–921) 714b (167–2812) 997b,c (218–16078)
Salivary cortisol (ng/mL)a 1.1 (0.1–14.9) 3.9b (0.3–11.8) 9.8b,c (1.4–771) 29.8b,c,d (2.8–750)
ACTH (pg/mL)a 17 (1–244) 4b (2–35) 47b,c (9–206) 185b,c,d (11–847)
DX Serum cortisol (μg/dLa) 1.1 (0.5–2.0) 14b (2.7–23.9) 14.4b (2.3–69.4) 37.7b (7.2–63.0)
aData for age and routine biochemistry are shown as medians and ranges. ACTH, adrenocorticotropin; DX, dexamethasone.
bP< 0.05, different from excluded.
cP< 0.02 pituitary or ectopic different from adrenal.
dP< 0.05 ectopic different from pituitary.
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exceeding 1.5 ng/mL; and lack of suppression of serum
cortisol (fasting serum cortisol 1.8 g/dL) with use of
the low-dose DST with 1 mg overnight or 2 mg over 2
days.
Subsequent diagnosis of ACTH-dependent and
independent CS and identification among the former
group of pituitary vs ectopic ACTH-secreting tumors
was based on various second-tier tests and imaging pro-
cedures carried out according to specific findings among
individual patients as outlined elsewhere (21 ). In total,
51 patients were identified with pituitary disease, 12 with
ectopic disease, and 21 with adrenal disease (Table 1).
Among the latter group, 17 had unilateral adenomas and
4 had bilateral micronodular or macronodular hyperpla-
sia. Surgical and pathological confirmation of disease,
with correction of hypercortisolism, was achieved in 79
(94%) patients. Three patients remained unoperated,
and 2 were treated medically. Diagnosis of a corticotroph
adenoma was confirmed later in 1 patient at autopsy.
Exclusion of CS was established by repeated bio-
chemical assessments and clinical follow-up after 3–12
months. A repeatedly negative low-dose DST result (fast-
ing serum cortisol 1.8 g/dL) and absent clinical evi-
dence of disease on follow-up represented the primary
final criteria for exclusion of CS. Patients with continu-
ing clinical suspicion and positive results of the DST,
including patients with indications of subclinical CS,
were excluded from analysis.
PLASMA STEROID PROFILING
All blood samples for plasma steroid profiling were col-
lected in the morning (08:00–11:00 AM) into blood
tubes containing lithium heparin or EDTA. Separated
plasma was stored at80 °C until the steroid profile was
analyzed by LC-MS/MS. The 15-adrenal steroid panel
included cortisol, 11-deoxycortisol, 21-deoxycortisol,
corticosterone, 11-deoxycorticosterone, aldosterone, 18-
oxocortisol, 18-hydroxycortisol, cortisone, progesterone,
17-hydroxyprogesterone, pregnenolone, androstene-
dione, dehydroepiandrosterone (DHEA), and DHEA-
sulfate (DHEA-SO4). Full details of the method, in-
cluding assay performance characteristics, are
described elsewhere (22 ).
STATISTICAL ANALYSES
Statistical analyses used the JMP statistics software pack-
age (SAS Institute). The Kruskal–Wallis and the Steel
Dwass all-pairs tests were used for nonparametric com-
parisons involvingmultiple groups. Spearman’s rank cor-
relation coefficient was used to assess significance of rela-
tionships. Significance was defined as P  0.05. For
parametric multivariate analyses, all data were logarith-
mically transformed before analyses. Because many of the
steroids in the plasma panel show sex-specific differences
and highly dynamic changes according to age, data for
plasma steroids shown in figures were normalized ac-
cording to age- and/or sex-specific upper cutoffs of refer-
ence intervals as established elsewhere (19 ). Receiver-
operating characteristic (ROC) curves for distinguishing
patients with and without CS were constructed by logis-
tic regression. Stepwise regression was used to select a
minimal panel of the most useful steroids for diagnosis.
Discriminant analysis with stepwise variable selection
was further used to assess how combinations of plasma
steroids could be used to distinguish various CS subtypes.
Data from the above analyses were compared to results of
diagnostic testing with use of routine tests.
Results
STEROID PROFILES
Patients in whom CS was suspected and excluded had
higher plasma concentrations of cortisol (P  0.0023),
18-oxocortisol (P  0.0001), and 18-hydroxycortisol
(P 0.0001) than the reference population; the remain-
ing 12 steroids showed no differences between the 2
groups without CS (Table 2). Among the 15 steroids in
the panel, 11-deoxycortisol and 11-deoxycorticosterone
were the only 2 that were consistently higher (P 
0.0001) in all subtypes of CS than in groups without CS.
While patients with pituitary and ectopic subtypes had
higher (P  0.0001) plasma concentrations of cortisol
than the 2 groups without CS, for patients with adrenal
CS the difference was only significant (P 0.0051) com-
pared to the reference group. Similarly, compared to the
2 groups without CS, patients with pituitary and ectopic
subtypes of CS had higher plasma concentrations of 21-
deoxycortisol (pituitary vs both groups, P 0.0001; ec-
topic vs reference, P  0.0004; ectopic vs rule-out, P 
0.0010), corticosterone (pituitary vs both groups, P 
0.0001; ectopic vs reference, P 0.0001; ectopic vs rule-
out, P 0.0004), and androstenedione (pituitary vs both
groups, P  0.0001; ectopic vs reference, P  0.0007;
ectopic vs rule-out, P  0.0053), whereas there were no
differences for those 3 steroids among patients with ad-
renal CS and the 2 groups without CS.
Similar to results for salivary and urinary free cortisol
(Table 1), patients with ectopic disease had the largest
increases of plasma glucocorticoids (Table 2). Plasma
concentrations of cortisol among patients with ectopic
ACTH secretion were higher than in patients with adre-
nal (P  0.0009) and pituitary CS (P  0.0047). Like-
wise, patients with ectopic disease had higher plasma
concentrations of 11-deoxycortisol (P  0.0040) and
11-deoxycorticosterone (P 0.0019) than patients with
pituitary CS, and higher (P  0.0194) corticosterone
concentrations than patients with adrenal CS.
Plasma concentrations of several other steroids
showed both distinctive and divergent differences among
different groups of CS patients compared to those with-
Cushing Syndrome Steroidomics
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out CS. In particular, plasma aldosterone was lower in
patients with pituitary CS (P  0.0040) and ectopic
ACTH secretion (P 0.0230) than in those in whomCS
was excluded (Table 2). Patients with ectopic disease also
had lower (P  0.0374) plasma aldosterone concentra-
tions than patients with adrenal CS. Similarly, plasma
18-oxocortisol concentrations were lower in patients
with ectopic ACTH secretion than in those with adrenal
CS (P 0.0427) and patients in whomCS was excluded
(P  0.0021).
The adrenal androgens showed an opposite pattern
to that of aldosterone and oxocortisol, with lower con-
centrations in adrenal CS than in pituitary CS (andro-
stenedione, P  0.0027; DHEA, P  0.0001; DHEA-
SO4, P  0.0001) and ectopic ACTH-secreting tumors
(androstenedione, P  0.0106; DHEA, P  0.0273;
DHEA-SO4, P  0.0380). Plasma DHEA and DHEA-
SO4 concentrations were also lower (P 0.0001) in the
adrenal CS group than in groups without CS. In contrast,
DHEA-SO4 was higher in patients with pituitary CS
than in the reference group (P 0.0048) and patients in
whom CS was excluded (P  0.0044). Differences
among patient groups for cortisone, 18-hydroxycortisol,
pregnenolone, 17-hydroxyprogesterone, and progester-
one were more isolated and less pronounced than for
other steroids.
Overall the various steroids in the panel showed dis-
tinctive patterns of differences between patients with
ACTH-independent and dependent forms of CS, in-
cluding among the latter group differences between pa-
tients with pituitary and ectopic subtypes (Fig. 1). In
part, the differences between the 2 ACTH-dependent
subtypes appeared to reflect the more pronounced nature
of disease in ectopic than pituitary disease (Table 1).
Nevertheless, the more pronounced nature of disease in
ectopic than pituitary subtypes was not reflected by all
steroids in the panel, in particular 18-oxocortisol,
DHEA, and DHEA-SO4.
RELATIONSHIPS OF STEROIDS AND ACTH
Among patients tested for CS, ACTH showed significant
positive relationships with all steroids except aldosterone,
18-oxocortisol, and progesterone (Table 3). For aldoste-
rone there was a significant negative relationship with
ACTH (rs  0.2626, P  0.0001). Apart from aldo-
sterone and 18-oxocortisol, the 13 other steroids of the
panel showed significant positive relationships for 92%
of all steroid comparisons. Aldosterone showed a strong
positive relationship with 18-oxocortisol (rs  0.6422,
P  0.0001), weaker relationships with 18-
hydroxycortisol (rs  0.1537, P  0.0006) and cortico-
sterone (rs  0.1332, P  0.0029), and considerably
Table 2. Plasma concentrations of 15 adrenal steroids in patients with adrenal, pituitary, and ectopic CS compared to the
reference population and patients in whom CS was suspected and excluded by routine biochemistry (see Table 1).
Tested for CS
Steroid Reference Excluded Adrenal Pituitary Ectopic
Cortisol 87 (10–308) 107a (5–419) 163a (30–266) 205a,b,c (21–444) 371a,b,c,d (141–1362)
11-Deoxycortisol 0.14 (0.03–1.82) 0.15 (0.01–0.86) 0.50a,b (0.08–5.33) 0.48a,b (0.05–3.63) 2.00a,b,d (0.30–34.1)
21-Deoxycortisol 0.01 (0.00–0.76) 0.01 (0.00–0.23) 0.01 (0.00–2.50) 0.03a,b (0.00–0.30) 0.04a,b (0.01–0.13)
Cortisone 17.2 (1.2–32.3) 18.9 (1.1–35.8) 17.8 (4.5–31.3) 21.3a,b (2.5–34.8) 23.2 (12.0–34.7)
Corticosterone 1.58 (0.17–32.00) 1.69 (0.07–16.90) 2.2 (0.49–11.45) 3.73a,b (0.23–16.90) 8.78a,b,c (1.61–30.30)
11-Deoxycorticosterone 0.03 (0.00–0.37) 0.03 (0.00–0.12) 0.09a,b (0.02–0.61) 0.05a,b,c (0.00–0.33) 0.19a,b,d (0.02–4.37)
Aldosterone 0.05 (0.00–0.27) 0.05 (0.00–0.67) 0.06 (0.01–1.09) 0.03a,b (0.01–0.31) 0.01b,c (0.01–0.17)
18-Oxocortisol 0.008 (0.001–0.09) 0.013a (0.003–0.33) 0.014a (0.002–0.50) 0.012 (0.01–0.07) 0.002b,c (0.002–0.03)
18-Hydroxycortisol 0.59 (0.03–2.59) 0.78a (0.02–5.86) 0.76 (0.22–4.20) 1.05a (0.07–5.32) 1.31a (0.26–3.44)
Pregnenolone 1.44 (0.18–11.20) 1.38 (0.04–10.50) 1.85 (0.15–6.06) 1.84b (0.15–5.58) 2.43 (0.15–10.26)
17-Hydroxyprogesterone 0.41 (0.04–2.74) 0.44 (0.06–1.90) 0.35 (0.04–6.43) 0.48 (0.04–2.36) 0.96b (0.20–6.83)
Progesterone 0.09 (0.01–26.10) 0.09 (0.04–13.40) 0.09 (0.01–11.16) 0.08 (0.01–10.11) 0.16d (0.01–11.16)
Androstenedione 0.87 (0.21–3.94) 0.97 (0.12–3.70) 0.49 (0.06–4.05) 1.70a,b,c (0.11–7.12) 1.99a,b,c (0.63–30.30)
DHEA 2.62 (0.40–16.90) 2.58 (0.03–25.9) 0.62a,b (0.04–11.55) 3.89c (0.03–13.00) 1.76c (0.52–18.90)
DHEA-SO4 1420 (135–6140) 1366 (25–4440) 238
a,b (5–6325) 2120a,b,c (33–5590) 1598c (29–5260)
All plasma concentrations are shown as medians and ranges in ng/mL.
aP< 0.05, different from reference.
bP< 0.05, different from excluded.
cP< 0.05 pituitary or ectopic different from adrenal.
dP< 0.05 ectopic different from pituitary.
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weaker (4/11) or nonexistent (7/11) relationships with
the other 11 steroids of the panel.
DIAGNOSIS OF CS
Urinary and salivary free cortisol showed considerable over-
lap among patients with and without CS (Fig. 2, A and B),
as did all 15 steroids in the plasma panel, including the 3
steroids (11-deoxycortisol, 11-deoxycorticosterone, and
cortisol) that provided the most consistent differences
among patient groups (Fig. 2, D–F). There was no overlap
for serumcortisol after dexamethasone (Fig. 2C).According
to the upper cutoffs of reference intervals for routine tests,
Fig. 1. Schematic diagram showing the biosynthetic pathways for the 15 adrenal steroids in the panel (black background) and 2
other steroids (light background) not included in the panel.
Also shown are the enzymes catalyzing each biosynthetic step. The exact pathways of synthesis shownby the gray dashed arrows for the hybrid
steroids, 18-hydroxycortisol and 18-oxocortisol, are incompletely established; however, synthesis of 18-oxocortisol is believed to depend on
metabolism of the glucocorticoid, 11-deoxycortisol, by aldose synthase (CYP11B2), an enzyme localizedmainly to the zona glomerulosa and
normally responsible in a multistep process for conversion of 11-deoxycorticosterone to aldosterone. The relative increases or decreases for
each plasma steroid compared to the reference population are shown for adrenal (A), pituitary (P), and ectopic (E) subtypes of CS, with extents
of increase or decrease indicated by the size of arrows or lack of difference by a dash (–).
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values for diagnostic sensitivity and specificity were 94.5%
and 65.3% for salivary free cortisol, 97.4% and 50.8% for
urinary free cortisol, and 100% and 97% for the DST. For
the steroid panel, upper cutoffs were individualized for age
and/or sex according to the 97.5 percentiles of our previ-
ously characterized reference population (19), yielding re-
spective diagnostic sensitivities and specificities of 61% and
99%for plasma11-deoxycortisol, 30%and99%for plasma
11-deoxycorticosterone, and 27% and 95% for plasma
cortisol.
Areas under ROC curves indicated higher (P 
0.001) diagnostic performance of the DST than any sin-
gle measurement or measurement combination (Fig. 2,
G and H). Salivary and urinary free cortisol exhibited
similar diagnostic performance and both showed higher
performance than plasma cortisol (P 0.0003). Urinary
free cortisol also showed higher diagnostic performance
than 11-deoxycortisol (P  0.0208), whereas there was
no difference between salivary cortisol and 11-
deoxycortisol (P  0.0891). With use of stepwise re-
gression analyses, a combination of 7 steroids (11-
deoxycortisol, 11-deoxcorticosterone, cortisol, aldosterone,
21-deoxycortisol, DHEA, and DHEA-SO4) was identi-
fied to provide optimal diagnostic performance for dis-
tinguishing patients with and without CS (Fig. 2H). The
area under the ROC curve for the 7-steroid combination
did not differ from areas for salivary or urinary free cor-
tisol and was higher than for any other single plasma
steroid in the panel (11-deoxycortisol, P  0.0408; cor-
tisol, P 0.0005; all 13 other steroids, P 0.0001). At
the optimal point in the ROC curve, the 7-steroid panel
offered a diagnostic sensitivity of 87% at a specificity of
89%.
DISCRIMINATION OF CS SUBTYPES
Complete results for routine measurements of salivary
and urinary free cortisol combined with the DST and
measurements of plasma ACTH were available in 173 of
all 222 patients tested for CS. By discriminant analysis,
use of the combination of 4 routine measurements cor-
rectly classified all patients with adrenal CS among the
total of 173 patients in whom the 4 routine measure-
ments were available (Fig. 3, A–C). Among that group of
173 patients, all of those in whom CS was excluded were
also correctly classified, and canonical plots indicated no
overlap between patients with ectopic or adrenal subtypes
from those in whom CS was excluded (Fig. 3A). Areas
under ROC curves varied from 0.9786 for ectopic disease
to 0.9987 for adrenal CS (Fig. 3B). Among all 173 pa-
tients, only 5.8% were not correctly classified by the
combination of all 4 routine measurements, this mainly
reflecting overlap for patients with pituitary and ectopic
subtypes among whom 80% were correctly identified
according to discriminant scores (Fig. 3C). Omitting ei-
ther salivary or urinary free cortisol from the 4-test com-
bination only slightly increased the misclassification rate
(7.3% and 9.0%). In contrast, omitting ACTH or the
DST more substantially increased misclassification to
21.4% and 13.7%, respectively, with the former reflect-
ing poorer discrimination of adrenal from pituitary and
ectopic subtypes and the latter poorer discrimination of
patients with and without CS.
By use of stepwise variable selection, a combination
of 10 plasma steroids (11-deoxycortisol, cortisol, corti-
sone, corticosterone, 11-deoxycorticosterone, andro-
stenedione, 18-oxocortisol, DHEA, DHEA-SO4, and al-
dosterone) in the panel were found to provide optimal
discrimination of the 3 subtypes of CS (Fig. 3, D–F).
Although canonical plots indicated more overlap with
use of the 10-steroid combination than with use of all 4
routine tests (Fig. 3, A and B), areas under ROC curves
were nevertheless similarly large, ranging from 0.9653 for
patients in whom CS was excluded to 1.000 for patients
with ectopic CS (Fig. 3E).
By use of the 10-steroid combination, all patients
with ectopic ACTH secretion were correctly classified,
only 1 patient with adrenal CS was incorrectly classified,
and most of the patients with pituitary CS were correctly
classified (Fig. 3F). The 10-steroid combination resulted
in incorrect classification of 9.5% of all patients, this
almost completely reflecting incomplete discrimination
of patients with and without CS (Fig. 3F).With addition
of the DST to the 10-steroid panel, misclassification fell
Table 3. Spearman correlation coefﬁcients (rs) and levels
of signiﬁcance for relationships of plasma ACTH with
steroids of the plasma panel.
Steroid rs value P-value
Cortisola 0.4852 <0.0001
11-Deoxycortisola 0.5733 <0.0001
21-Deoxycortisola 0.3275 <0.0001
Cortisonea 0.2914 <0.0001
Corticosteronea 0.4988 <0.0001
11-Deoxycorticosteronea 0.3496 <0.0001
Aldosterone −0.2626 <0.0001
18-Oxocortisol −0.1029 0.1281
18-Hydroxycortisola 0.3070 <0.0001
Pregnenolonea 0.2084 0.0031
17-Hydroxyprogesteronea 0.1868 0.0082
Progesteronea 0.0537 0.4511
Androstenedione 0.3940 <0.0001
DHEA 0.3477 <0.0001
DHEA-SO4 0.3846 <0.0001
aAnalysis for these steroids omits data for adrenal CS patients.
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Fig. 2. Results of routine diagnostic tests (A, B, C, G) and selected steroids (D, E, F, H) of the 15-steroid panel in patientswith CS (CS)
and in patients in whom CS was excluded (EX).
Absolute values for urinary free cortisol (A), salivary free cortisol (B), andDSTplasma cortisol concentrations (C) are shownwith respect toupper cutoffs
of reference intervals used in routine clinical practice. Values for the 3 selected steroids, 11-deoxycortisol (D), 11-deoxycorticosterone (E), and cortisol
(F), of the15-steroidpanel are shownasaproportionof sex- andage-speciﬁcupper cutoffs (relUC) forwhichupper cutoffs aredesignatedwitha value
of 1. Among thedifferent patientswith andwithout CS, the4groups aredistinguishedbydifferent symbols (ectopic CS , pituitary CS , adrenal
CS , CS excluded ). ROC curves are shown in panel G for the 3 routine screening tests and in panelH for plasma cortisol, 11-deoxycortisol, and
a selection of 7 steroids of the steroid panel that provided optimal discrimination of patients with andwithout CS.
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Fig.3. Resultsofdiscriminantanalyses foruseof routinediagnostic tests (A,B,C) comparedto10steroidsof thesteroidpanel (D,E,F) that
provided optimal discrimination of the 4 patient groups (ectopic CS , pituitary CS , adrenal CS , CS excluded ).
Three-dimensional canonical plots are shown in panels A and D; ROC curves with areas under curves are shown in panels B and C; whereas
predicted versus actual groupings according to discriminant analyses are shown in panels C and F. Routine diagnostic tests included mea-
surements of salivary and urinary free cortisol, DST plasma cortisol, and ACTH. Steroids for the selected steroid proﬁle included 11-
deoxycortisol, corticosterone, 11-deoxycorticosterone, cortisol, corticosterone, DHEA, DHEA-SO4, androstenedione, aldosterone, and 18-
oxocortisol. Note that for the analyses of routine clinical tests, complete results for all 4 tests were only available in 173 of the 222 patients.
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to 4.9% and no patient with CS was incorrectly desig-
nated not to have CS.
Discussion
This study using simultaneous LC-MS/MS measure-
ments of 15 adrenal steroids in plasma establishes distinct
steroid metabolome profiles that might be useful as a test
for CS. Specimen preparation is simple, the entire panel
takes 12min to run, and the method has the potential for
offering a single test for both screening of CS and initial
subtype classification. Another advantage over other tests
is that different selections of steroids from the panel may
be used for other disorders of adrenal steroidogenesis,
including primary aldosteronism, adrenocortical carci-
noma, and congenital adrenal hyperplasia (14, 15, 17 ),
providing versatility of the method.
LC-MS/MS is rapidly gaining recognition as the
method of choice for accurate measurements of specific
steroids and other low molecular weight analytes used in
the diagnosis of endocrine disorders. Applications of LC-
MS/MS are now also being increasingly developed for
targeted analyses of multiple analytes. Gas chromatogra-
phy coupled to mass spectrometry also offers a useful
analytical platform for multisteroid profiling in adrenal
disorders (23–26). However, these methods invariably
involve labor-intensive sample processing, including the
necessity of a derivatization step, and offer limited sample
throughput due to extended chromatographic run times.
Consequently, LC-MS/MS offers a preferable platform,
particularly for routine clinical purposes (27, 28 ).
Among the steroids examined, 11-deoxycortisol, the
immediate precursor of cortisol, showed the strongest
diagnostic signal for distinguishing patients with and
without CS. Recently, plasma 11-deoxycortisol and its
urinary metabolite, tetrahydro-11-deoxycortisol, were
also shown to provide the best steroid biomarkers for
adrenocortical carcinoma (17, 18 ). In other studies, 11-
deoxycortisol was superior to cortisol for identifying pa-
tients with adrenal insufficiency and indicating correct
catheter positions during adrenal venous sampling
(13, 22, 29 ). Poor diagnostic utility of plasma cortisol
compared to salivary or urinary free cortisol and other
indices of glucocorticoid production, such as 11-
deoxycortisol, may result both from the considerable
amounts bound to cortisol-binding globulin as well as im-
pacts of the cortisol-cortisone shunt (30, 31). In the present
study, diagnostic performance for 11-deoxycortisol was
strengthened by addition of other steroids in a 7-steroid
combination that together provided similar diagnostic per-
formance to salivary free cortisol.
Although indicating some promise for diagnosis of
CS, inspection of ROC curves for the various tests exam-
ined for distinguishing patients with and without CS
indicates that the selected 7-steroid combination is un-
likely to offer a single-test replacement for all 4 currently
recommended screening tests, particularly the DST.
Nevertheless, it should also be appreciated that the ap-
parently exceptional diagnostic performance of the DST
in the present analysis is misleading, since patients with
positive DST results (i.e., a serum cortisol of 1.8 g/dL)
and no confirmation of CS were excluded from the anal-
ysis. Although a cutoff of 1.8 g/dL for a post DST
plasma cortisol is useful for identifying about 95% of
patients with CS and excluding CS in almost all patients
with lower values, this cutoff is associated with false-
positive rates of around 20%, indicating inadequate spec-
ificity for excluding CS in all disease-free patients
(32, 33 ). Thus, the area under the ROC curve of 1.0 for
the DST is a misleading artifact resulting from the neces-
sity to examine plasma steroid profiles in well-defined
populations of patients with and without CS.
Measurements of steroid profiles before and after the
DST might offer improved diagnostic performance over
single plasma cortisol measurements. In this case it would
also be a simple matter to include measurements of
plasma dexamethasone in the panel to further improve
diagnostic performance (34, 35 ). Increased diagnostic
performance of the 7-steroid panel, above that for late-
night salivary cortisol, might also be expected for blood
sampling at night rather than in the morning. Neverthe-
less, the ease and simplicity of sampling saliva without
need for an overnight hospital stay offers advantages for
salivary over plasma measurements. With availability of
more analytically sensitive mass spectrometers, it might
become possible to examine steroid profiles in saliva or
even hair (36 ).
Our findings that the various subtypes of CS show
distinctive steroid fingerprints support previous findings
of different steroid profiles in ACTH-dependent and in-
dependent forms of CS (4, 17, 18, 37 ). In particular,
low urinary excretion of DHEA in adrenal CS compared
to pituitary disease (4 ) was subsequently determined to
extend to a similar pattern for serum DHEA-SO4 (37 ).
Reduced plasma concentrations of DHEA and andro-
stenedione have also been documented by LC-MS/MS
measurements in patients with subclinical CS compared
to age-matched controls (16 ). More recently, 2 further
independent studies confirmed lower plasma and urinary
androgens in ACTH-independent CS than in ACTH-
dependent forms of CS (17, 18 ).
In contrast to the pattern for androgens, the much
lower plasma concentrations of aldosterone in ACTH-
dependent CS than in independent forms of CS is not
clearly established in the literature. In one study, plasma
concentrations of aldosterone were reported to be sup-
pressed in pituitary CS (38 ), whereas other reports
yielded conflicting results (39, 40 ). Possibly suppressed
aldosterone may reflect reduced renin activity secondary
to fluid and salt retention in the more severe forms of CS
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associated with pituitary and ectopic compared to adre-
nal disease. Interestingly, 18-oxocortisol also showed low
plasma concentrations confined to patients with ectopic
CS, a finding that might reflect suppression of the last
enzymatic step in conversion of 11-deoxycortisol to 18-
oxocortisol by aldosterone synthase (41 ).
Apart from the aforementioned differences in aldo-
sterone, hybrid steroids, and adrenal androgens, the var-
ious groups were also characterized by differences
in other steroids such as corticosterone and 11-
deoxycorticosterone. Combined with 11-deoxycortisol,
cortisol, and cortisone, these steroids provided a 10-
steroid panel that identified the various subtypes of CS
with near comparable effectiveness as the combination of
all routine diagnostic tests. Although the routine test
combination was expectedly more effective than the
plasma steroid profile for distinguishing patients with
ACTH-dependent and independent CS, the plasma ste-
roid profile appeared to show heightened effectiveness for
distinguishing ectopic from pituitary and adrenal disease.
Furthermore, by combining plasma steroid profiles with
the DST, discrimination was as effective as all 4 routine
tests.
While mass spectrometric assays of the steroid
metabolome are unlikely to offer a single test alternative
to all currently recommended screening tests for CS, the
plasma steroid panel may be useful as a supplementary
single-test alternative to both screen for CS and guide
second-tier testing for discrimination of the 3 main CS
subtypes. In this way, use of the plasma steroid panel as
an alternative to measurements of urinary and salivary
free cortisol might offer a cost-effective approach for
streamlining the diagnostic process by reducing the num-
ber of screening and follow-up tests to confirm or exclude
CS, as well as decreasing the number of subsequent
second-tier steps ahead of procedures to localize tumors
within the adrenal, pituitary, or at sources of ectopic
ACTH secretion.
The retrospective nature of the study, with reliance
on routine tests to rule out CS, represents a limitation of
the present analysis. Indeed, findings of slight but signif-
icant differences in plasma cortisol, 18-oxocortisol, and
18-hydroxycortisol between patients in whom CS was
excluded and the reference group suggest that within the
former group there may have been patients with subtle
hypercortisolism who were not identified by routine
tests. This and the need to exclude patients in whom CS
could not be ruled out by the DST represent shortcom-
ings ensuring that it could not be possible to determine
any significant improvement in diagnostic performance
of the plasma steroid metabolome compared to routine
diagnostic tests. Inclusion of a validation cohort would
also have been useful, underlying the importance of fur-
ther prospective studies to confirm the results of the pres-
ent series. With the above limitations aside, the study
remains important for providing novel data about a dis-
ease for which there remains considerable need for more
effective and efficient strategies for diagnosis and subtype
classification.
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